

Czechia

Population 2015

11 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.039 (0.039–0.039)	0.37 (0.37–0.37)
Mortality (HIV+TB only)	<0.01 (0–<0.01)	0.01 (0–0.04)
Incidence (includes HIV+TB)	0.55 (0.47–0.63)	5.2 (4.4–6)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.06 (0.04–0.07)
Incidence (MDR/RR-TB)**	0.015 (<0.01–0.026)	0.14 (0.04–0.25)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.014 (<0.01–0.023)	0.16 (0.098–0.22)	0.17 (0.1–0.24)
Males	0.022 (0.014–0.029)	0.35 (0.28–0.43)	0.37 (0.29–0.45)
Total	0.036 (0.026–0.046)	0.51 (0.46–0.55)	0.55 (0.47–0.63)

TB case notifications, 2015

Total cases notified	518
Total new and relapse	508
- % tested with rapid diagnostics at time of diagnosis	46%
- % with known HIV status	36%
- % pulmonary	87%
- % bacteriologically confirmed among pulmonary	85%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	93% (81–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.07 (0.06–0.09)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	2	1%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			13 (3–22)
Estimated % of TB cases with MDR/RR-TB	1.7% (0.56–4)	13% (1.7–40)	
% notified tested for rifampicin resistance	73%	64%	372
MDR/RR-TB cases tested for resistance to second-line drugs			8
Laboratory-confirmed cases		MDR/RR-TB: 10, XDR-TB: 1	
Patients started on treatment ****		MDR/RR-TB: 10, XDR-TB: 1	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	76%	467
Previously treated cases, excluding relapse, registered in 2014	65%	37
HIV-positive TB cases, all types, registered in 2014	0%	1
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

National TB budget (US\$ millions)

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB